Related Experiment Video
Updated: Apr 6, 2026
12:37
Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
Published on: February 9, 2016
14.0K
Gender Differences in Cardiovascular Drugs.
Amanda J Stolarz1, Nancy J Rusch
1Department of Pharmacology and Toxicology, College of Medicine, and College of Pharmacy, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Mail Slot 611, Little Rock, AR, 72205-7199, USA, astolarz@uams.edu.
Cardiovascular Drugs and Therapy
|August 1, 2015
Summary
Cardiovascular drug responses differ between women and men due to physiological variances. Understanding these gender-specific effects is crucial for optimizing cardiovascular drug therapy and improving patient safety.
Area of Science:
- Pharmacology
- Cardiology
- Sex-Based Medicine
Background:
- Cardiovascular drug efficacy and safety vary between sexes.
- Physiological and sensitivity differences influence drug responses.
- Existing data often underrepresents women in clinical trials.
Purpose of the Study:
- To review gender-related differences in responses to common cardiovascular drugs.
- To highlight the impact of sex-specific pharmacokinetics and pharmacodynamics.
- To inform risk/benefit assessments for cardiovascular medications in women.
Main Methods:
- Literature review of studies examining gender differences in cardiovascular drug response.
- Analysis of pharmacokinetic and pharmacodynamic data stratified by sex.
- Examination of adverse event profiles, including arrhythmias and QT interval prolongation.
Main Results:
- Women and men exhibit distinct responses to cardiovascular drugs like statins, antiplatelet agents, and beta-blockers.
- Gender-specific pharmacokinetic profiles affect drug metabolism and distribution.
- Women show increased risk for certain adverse effects, such as QT interval prolongation and associated arrhythmias.
Conclusions:
- Gender is a critical factor in cardiovascular drug prescribing and dosage adjustment.
- Incorporating sex-specific data enhances the precision of cardiovascular pharmacotherapy.
- Further research and inclusion of women in clinical trials are essential for personalized medicine.
More Related Videos
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
325
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
325
01:22Heart Failure Drugs: β-Blockers
1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:21Factors Affecting Drug Response: Overview
3.3K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.3K
01:16Antianginal Drugs: Nitrates and β-Blockers
1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K